Skip to main
HNGE

HNGE Stock Forecast & Price Target

HNGE Analyst Ratings

Based on 16 analyst ratings
Buy
Strong Buy 38%
Buy 56%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

Hinge Health Inc. is experiencing substantial momentum, with expectations of a significant increase in client count in the fourth quarter of 2025, reflecting a strong pipeline for late-stage deals heading into 2026. The company is projecting a robust adjusted operating income margin of approximately 22.4% for the fourth quarter of 2025, which represents a notable improvement of 270 basis points year-over-year. Additionally, Hinge Health delivered an impressive 53.3% revenue growth and expanded its adjusted operating margins by 23 points year-over-year, signaling strong financial health and operational efficiency.

Bears say

Hinge Health Inc. demonstrates a declining adjusted R&D ratio from 23.7% of revenue in 3Q24 to 14.5% in 3Q25, suggesting a potential inability to maintain innovation in a competitive landscape. The bear case scenario anticipates a challenging macroeconomic environment in 2H25, which could lead to slower growth in FY26, compounded by a projected sequential decline in membership for 4Q25. Furthermore, the anticipated mid-teens EBIT margins in 2H25, along with a lower expected EV/revenue multiple due to the firm’s reliance on employee utilization for revenue growth, underscores the financial risks associated with Hinge Health's operational model.

HNGE has been analyzed by 16 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 56% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hinge Health Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hinge Health Inc (HNGE) Forecast

Analysts have given HNGE a Buy based on their latest research and market trends.

According to 16 analysts, HNGE has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $60.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $60.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hinge Health Inc (HNGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.